Navigation Links
Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
Date:3/23/2009

TORONTO, March 23 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) announced today that the first patient has been dosed in a clinical study of gastrin analogue TT-223 in combination with a proprietary Lilly GLP-1 analogue, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of GLP-1 analogue, for a combination treatment period of 4 weeks with a 5-month follow-up.

For information on enrollment, patients or caregivers can visit the website www.clinicaltrials.gov under study # NCT00853151

    About Gastrin-Based Therapies
    -----------------------------

Transition and Eli Lilly and Company (NYSE: LLY) have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize gastrin based therapies, including the lead compound TT-223. Gastrin based therapies are an emerging class of potential disease-modifying therapies for patients with diabetes, and have been shown to provide sustained improvement in glycemic control in preclinical models and early clinical studies. Sustained improvement in glycemic control is a key goal for patients with diabetes in order to alleviate the symptoms of hyperglycemia and to prevent diabetic complications, and improving their overall quality of life.

    About Transition
    ----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Transition of Chief Financial Officer
2. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
3. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
4. CDS Completes Large-Scale Transition of Medicare Data Processing
5. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
6. Is rapid transition through menopause linked to earlier onset of heart disease?
7. MEDai Presents on Transitioning Predictive Modeling Integration From Care Management to Actuarial Applications
8. Mental Health Leaders Meet with Transition Team
9. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
10. AUDIO from Medialink and Transitions Optical: New Years Resolutions for Healthier Eyes
11. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive family ... Brian Seese leads the practice as a skilled and highly credentialed dentist who is ... Seese serves patients of all ages with excellence in general, restorative, and cosmetic ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 ... questions manufacturers should be asking before selecting an FDA approval pathway? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve more than ... the U.S. Soccer Foundation announced today that they have awarded nine grants to ... the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 20, 2017  Today from HIMSS17, Ambra Health ... suite, announced the launch of  Ambra for Developers ... Built around modern, RESTful web-services, this is the first ... With these new APIs, IT departments at health ... data into other applications such as population health or ...
(Date:2/20/2017)... Feb 20, 2017 Research and Markets ... Global Market -Forecast to 2022" report to their offering. ... ... in aging population, rising adoption of tension free repair procedures ... growth of hernia repair devices global market. However, Inconsistent reimbursement ...
(Date:2/20/2017)... Feb. 20, 2017  There has been a paradigm ... (NCDs) across sub-Saharan Africa, which in turn is driving ... of more Western lifestyle diseases such as cardiovascular disease ... infectious and parasitic illness, will present the pharmaceutical industry ... opportunity of $40.8 billion in 2019. "An ...
Breaking Medicine Technology: